<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132979">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02128178</url>
  </required_header>
  <id_info>
    <org_study_id>Enoxaparin</org_study_id>
    <nct_id>NCT02128178</nct_id>
  </id_info>
  <brief_title>Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study</brief_title>
  <official_title>Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <authority>Egypt: Mansoura university hospital</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obese patients undergoing bariatric surgery warrant VTE prophylaxis because they are at high
      risk for developing a fatal pulmonary embolism or postthrombotic syndrome. However, a
      consensus does not exist on the most effective prophylactic approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two regimens of prophylaxis are supposed , the 1st one is to give enoxaparin 40mg 2 hours
      before surgery and continued daily for 10 days after, and the 2nd one is to start 12 hours
      before surgery and continued in the same way like the 1st one.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Venous thrombosis and/or pulmonary embolism (PE)</measure>
    <time_frame>Postoperative 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the venous thrombosis by compression ultrasonography and PE in suspected patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding from the surgery site , drain if any, GIT bleeding,</measure>
    <time_frame>postoperative 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bleeding from drain, GIT, or wounds are assessed clinically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>4 WEEKS</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>hospital stay in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Morbid Obesity</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>ENOXAPARIN 2 HOURS BEFORE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 40 mg 12 hours before</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 40 mg 2 hours before arm</intervention_name>
    <description>Enoxaparin 40 mg 2 hours before surgery</description>
    <arm_group_label>ENOXAPARIN 2 HOURS BEFORE</arm_group_label>
    <other_name>First group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 40 mg 12 hours before arm</intervention_name>
    <description>Enoxaparin 40 mg 12 hours before surgery</description>
    <arm_group_label>Enoxaparin 40 mg 12 hours before</arm_group_label>
    <other_name>second group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt;40 OR &gt;35 with comorbidities

        Exclusion Criteria:

          -  No
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohamed e abd ellatif, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mohamed e abd ellatif, phd</last_name>
    <email>surg_latif@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manoura University</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed e abd ellatif, phd</last_name>
      <email>surg_latif@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>mohamed e abd ellatif, phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>MOHAMED ABDELLATIF</investigator_full_name>
    <investigator_title>phd</investigator_title>
  </responsible_party>
  <keyword>Morbid obesity</keyword>
  <keyword>Laparoscopic surgery</keyword>
  <keyword>Compression ultrasonography</keyword>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Bleeding</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
